Loading…
HDR Brachytherapy in the Management of High-Risk Prostate Cancer
High-dose-rate (HDR) brachytherapy is used with increasing frequency for the treatment of prostate cancer. It is a technique which allows delivery of large individual fractions to the prostate without exposing adjacent normal tissues to unacceptable toxicity. This approach is particularly favourable...
Saved in:
Published in: | Advances in Urology 2012-01, Vol.2012 (2012), p.798-803 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-a638t-54312c29e8e56f5f6b6bac62ceb25356cd211282b5e63e84b294e3a1730c44ca3 |
---|---|
cites | cdi_FETCH-LOGICAL-a638t-54312c29e8e56f5f6b6bac62ceb25356cd211282b5e63e84b294e3a1730c44ca3 |
container_end_page | 803 |
container_issue | 2012 |
container_start_page | 798 |
container_title | Advances in Urology |
container_volume | 2012 |
creator | Masson, Susan Persad, Raj Bahl, Amit |
description | High-dose-rate (HDR) brachytherapy is used with increasing frequency for the treatment of prostate cancer. It is a technique which allows delivery of large individual fractions to the prostate without exposing adjacent normal tissues to unacceptable toxicity. This approach is particularly favourable in prostate cancer where tumours are highly sensitive to dose escalation and to increases in radiotherapy fraction size, due to the unique radiobiological behaviour of prostate cancers in contrast with other malignancies. In this paper we discuss the rationale and the increasing body of clinical evidence for the use of this technique in patients with high-risk prostate cancer, where it is combined with external beam radiotherapy. We highlight practical aspects of delivering treatment and discuss toxicity and limitations, with particular reference to current practice in the United Kingdom. |
doi_str_mv | 10.1155/2012/980841 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_98c415397e8340cb96f303f4c37e553c</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><airiti_id>P20151223003_201212_201703140007_201703140007_798_803</airiti_id><doaj_id>oai_doaj_org_article_98c415397e8340cb96f303f4c37e553c</doaj_id><sourcerecordid>963493136</sourcerecordid><originalsourceid>FETCH-LOGICAL-a638t-54312c29e8e56f5f6b6bac62ceb25356cd211282b5e63e84b294e3a1730c44ca3</originalsourceid><addsrcrecordid>eNqFkcuP0zAQhyMEYpeFE2dQbkigsLbHzwsCyqMrFbFawdmauJPWpU2Kk4L63-NtloqeOM3Y8-nz41cUTzl7zblSl4Jxcekss5LfK865tqbSYMz9Y6_dWfGo71eMaW6NeVicCSE1N46fF2-nH27K9wnDcj8sKeF2X8a2zG35BVtc0IbaoeyachoXy-om9j_K69T1Aw5UTrANlB4XDxpc9_Tkrl4U3z99_DaZVrOvn68m72YVarBDpSRwEYQjS0o3qtG1rjFoEagWCpQOc8G5sKJWpIGsrIWTBMgNsCBlQLgorkbvvMOV36a4wbT3HUZ_2OjSwmMaYliTdzZIrsAZsiBZqJ1ugEEjAxhSCkJ2vRld2129oXnIb0y4PpGeTtq49IvulwfhNFcsC17cCVL3c0f94DexD7ReY0vdrvdOg3TAQWfy1UiG_G19ouZ4Cmf-Nj5_G58f48v0838vdmT_5pWBlyOwjO0cf8f_2J6NMGWEGjzCioM4zGfjHGOKQ_SrbpfanKG_zhbFhQDG4GDMzlwMAy4ZY-Z0YZz1lgH8AQh6vho</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>963493136</pqid></control><display><type>article</type><title>HDR Brachytherapy in the Management of High-Risk Prostate Cancer</title><source>Wiley Open Access</source><source>PubMed Central</source><creator>Masson, Susan ; Persad, Raj ; Bahl, Amit</creator><contributor>Spahn, Martin</contributor><creatorcontrib>Masson, Susan ; Persad, Raj ; Bahl, Amit ; Spahn, Martin</creatorcontrib><description>High-dose-rate (HDR) brachytherapy is used with increasing frequency for the treatment of prostate cancer. It is a technique which allows delivery of large individual fractions to the prostate without exposing adjacent normal tissues to unacceptable toxicity. This approach is particularly favourable in prostate cancer where tumours are highly sensitive to dose escalation and to increases in radiotherapy fraction size, due to the unique radiobiological behaviour of prostate cancers in contrast with other malignancies. In this paper we discuss the rationale and the increasing body of clinical evidence for the use of this technique in patients with high-risk prostate cancer, where it is combined with external beam radiotherapy. We highlight practical aspects of delivering treatment and discuss toxicity and limitations, with particular reference to current practice in the United Kingdom.</description><identifier>ISSN: 1687-6369</identifier><identifier>EISSN: 1687-6377</identifier><identifier>DOI: 10.1155/2012/980841</identifier><identifier>PMID: 22461791</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Limiteds</publisher><subject>Review</subject><ispartof>Advances in Urology, 2012-01, Vol.2012 (2012), p.798-803</ispartof><rights>Copyright © 2012 Susan Masson et al.</rights><rights>Copyright © 2012 Susan Masson et al. 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a638t-54312c29e8e56f5f6b6bac62ceb25356cd211282b5e63e84b294e3a1730c44ca3</citedby><cites>FETCH-LOGICAL-a638t-54312c29e8e56f5f6b6bac62ceb25356cd211282b5e63e84b294e3a1730c44ca3</cites><orcidid>0000-0001-7747-0412</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296150/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296150/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22461791$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Spahn, Martin</contributor><creatorcontrib>Masson, Susan</creatorcontrib><creatorcontrib>Persad, Raj</creatorcontrib><creatorcontrib>Bahl, Amit</creatorcontrib><title>HDR Brachytherapy in the Management of High-Risk Prostate Cancer</title><title>Advances in Urology</title><addtitle>Adv Urol</addtitle><description>High-dose-rate (HDR) brachytherapy is used with increasing frequency for the treatment of prostate cancer. It is a technique which allows delivery of large individual fractions to the prostate without exposing adjacent normal tissues to unacceptable toxicity. This approach is particularly favourable in prostate cancer where tumours are highly sensitive to dose escalation and to increases in radiotherapy fraction size, due to the unique radiobiological behaviour of prostate cancers in contrast with other malignancies. In this paper we discuss the rationale and the increasing body of clinical evidence for the use of this technique in patients with high-risk prostate cancer, where it is combined with external beam radiotherapy. We highlight practical aspects of delivering treatment and discuss toxicity and limitations, with particular reference to current practice in the United Kingdom.</description><subject>Review</subject><issn>1687-6369</issn><issn>1687-6377</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqFkcuP0zAQhyMEYpeFE2dQbkigsLbHzwsCyqMrFbFawdmauJPWpU2Kk4L63-NtloqeOM3Y8-nz41cUTzl7zblSl4Jxcekss5LfK865tqbSYMz9Y6_dWfGo71eMaW6NeVicCSE1N46fF2-nH27K9wnDcj8sKeF2X8a2zG35BVtc0IbaoeyachoXy-om9j_K69T1Aw5UTrANlB4XDxpc9_Tkrl4U3z99_DaZVrOvn68m72YVarBDpSRwEYQjS0o3qtG1rjFoEagWCpQOc8G5sKJWpIGsrIWTBMgNsCBlQLgorkbvvMOV36a4wbT3HUZ_2OjSwmMaYliTdzZIrsAZsiBZqJ1ugEEjAxhSCkJ2vRld2129oXnIb0y4PpGeTtq49IvulwfhNFcsC17cCVL3c0f94DexD7ReY0vdrvdOg3TAQWfy1UiG_G19ouZ4Cmf-Nj5_G58f48v0838vdmT_5pWBlyOwjO0cf8f_2J6NMGWEGjzCioM4zGfjHGOKQ_SrbpfanKG_zhbFhQDG4GDMzlwMAy4ZY-Z0YZz1lgH8AQh6vho</recordid><startdate>20120101</startdate><enddate>20120101</enddate><creator>Masson, Susan</creator><creator>Persad, Raj</creator><creator>Bahl, Amit</creator><general>Hindawi Limiteds</general><general>Hindawi Puplishing Corporation</general><general>Hindawi Publishing Corporation</general><general>Hindawi Limited</general><scope>188</scope><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7747-0412</orcidid></search><sort><creationdate>20120101</creationdate><title>HDR Brachytherapy in the Management of High-Risk Prostate Cancer</title><author>Masson, Susan ; Persad, Raj ; Bahl, Amit</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a638t-54312c29e8e56f5f6b6bac62ceb25356cd211282b5e63e84b294e3a1730c44ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Masson, Susan</creatorcontrib><creatorcontrib>Persad, Raj</creatorcontrib><creatorcontrib>Bahl, Amit</creatorcontrib><collection>Airiti Library</collection><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Advances in Urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Masson, Susan</au><au>Persad, Raj</au><au>Bahl, Amit</au><au>Spahn, Martin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HDR Brachytherapy in the Management of High-Risk Prostate Cancer</atitle><jtitle>Advances in Urology</jtitle><addtitle>Adv Urol</addtitle><date>2012-01-01</date><risdate>2012</risdate><volume>2012</volume><issue>2012</issue><spage>798</spage><epage>803</epage><pages>798-803</pages><issn>1687-6369</issn><eissn>1687-6377</eissn><abstract>High-dose-rate (HDR) brachytherapy is used with increasing frequency for the treatment of prostate cancer. It is a technique which allows delivery of large individual fractions to the prostate without exposing adjacent normal tissues to unacceptable toxicity. This approach is particularly favourable in prostate cancer where tumours are highly sensitive to dose escalation and to increases in radiotherapy fraction size, due to the unique radiobiological behaviour of prostate cancers in contrast with other malignancies. In this paper we discuss the rationale and the increasing body of clinical evidence for the use of this technique in patients with high-risk prostate cancer, where it is combined with external beam radiotherapy. We highlight practical aspects of delivering treatment and discuss toxicity and limitations, with particular reference to current practice in the United Kingdom.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Limiteds</pub><pmid>22461791</pmid><doi>10.1155/2012/980841</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-7747-0412</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1687-6369 |
ispartof | Advances in Urology, 2012-01, Vol.2012 (2012), p.798-803 |
issn | 1687-6369 1687-6377 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_98c415397e8340cb96f303f4c37e553c |
source | Wiley Open Access; PubMed Central |
subjects | Review |
title | HDR Brachytherapy in the Management of High-Risk Prostate Cancer |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T14%3A07%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HDR%20Brachytherapy%20in%20the%20Management%20of%20High-Risk%20Prostate%20Cancer&rft.jtitle=Advances%20in%20Urology&rft.au=Masson,%20Susan&rft.date=2012-01-01&rft.volume=2012&rft.issue=2012&rft.spage=798&rft.epage=803&rft.pages=798-803&rft.issn=1687-6369&rft.eissn=1687-6377&rft_id=info:doi/10.1155/2012/980841&rft_dat=%3Cproquest_doaj_%3E963493136%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a638t-54312c29e8e56f5f6b6bac62ceb25356cd211282b5e63e84b294e3a1730c44ca3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=963493136&rft_id=info:pmid/22461791&rft_airiti_id=P20151223003_201212_201703140007_201703140007_798_803&rfr_iscdi=true |